Asia’s Largest Web3 Event TOKEN2049 Exclusively Unveils NFT Assets Valued Over US$100 Million
22.9.2022 04:40:00 EEST | Business Wire | Press release
TOKEN2049, Asia’s premier crypto conference, announced that it will be showcasing a first-of-its-kind, immersive NFT experience, entitled the OP3N WHALE NFT Exhibition, at its upcoming Singapore edition from 28 to 29 September. The exhibition will be presenting NFT assets with a market value exceeding US$100 million — the first time such a collection owned by a single entity has ever been on display to the public.
The exhibition was developed by OP3N, a launchpad for IP and communities in Web3, and WHALE, the omni-versal membership club with a treasury that includes the world’s largest collection of rare, high-value NFTs spanning gaming, art, and virtual real estate.
Raphael Strauch, Founder of TOKEN2049 said: “Today’s Web3 ecosystem reflects the exciting creativity and innovation being brought by a myriad of industries by way of their growing interest in NFTs — and so much of this is taking place in Asia. We have an exciting programme for our attendees — and this exhibition is just one part.”
Showcasing creatives, brands, and curators from the region that exemplify the global dynamic of East Meets West, the exhibition will make its exclusive debut at Asia’s largest Web3 event and TOKEN2049’s largest-ever conference in its history. An estimated 7,000 visitors are expected to attend.
The exhibition includes artworks by renowned digital artist Pak, famed for spearheading Sotheby’s first-ever NFT sale; leading glitch artist XCOPY; Milanese artist duo Hackatao; and award-winning Asian-American photographer Michael Yamashita.
TOKEN2049 Singapore will also feature a rotating display of generative art masterpieces from New York City’s Museum of Modern Art (MoMA)’s permanent collection artist Brendan Dawes and Instagram photography sensation Ryosuke Kosuge. These works will be displayed at WHALE’s solo booth at the conference.
Renowned NFT collector and WHALE founder WhaleShark, said: “Non Fungible technology has ignited a global digital renaissance of art and culture, and the ability to partner with TOKEN2049 and OP3N to showcase some of the earliest and most renowned pioneers of this sector is truly an honor. The exhibition puts the spotlight on this inevitable revolution of the arts with a focus on a time-tested creative industry rather than the flavor of the month.”
In addition, attendees will be able to see OP3N’s latest NFT drop “A3”, developed by YOON and VERBAL who are behind the iconic Tokyo-based fashion brand AMBUSH®. The iconic phygital “A3” NFT will be uniquely presented in a glass display case on the exhibition floor.
“Art, culture and technology are intersecting in exciting and completely new ways, with many industry firsts taking place around the globe,” said Jaeson Ma, Co-Chief Executive Officer and Founder of OP3N, the world’s preeminent contemporary NFT experience brand. “From digital creators and traditional artists to fashion brands such as AMBUSH who’s been expanding their presence in the NFT space, we’re bringing together an incredible pool of talent to celebrate and honor their work.”
Jaeson will also be speaking on a panel on ‘The Future of IP & Communities in Web3’ on 29 September at 2:45 PM along with VERBAL who will speak more about “A3” in detail.
TOKEN2049 Singapore’s agenda will be featuring a series of discussions touching on the latest developments in the Web3 ecosystem — from the global macro narrative for crypto, the rise of Web3 gaming, the emerging social and creator economy, the future of AI and generative art, present and future Web3 infrastructure, and many more.
As part of Asia Crypto Week, TOKEN2049 attendees can expect to attend a full line-up of side events, conferences, networking events, workshops, and parties taking place throughout the week.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/.
About TOKEN2049
TOKEN2049 is a premier Web3 event, organized annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
About OP3N
Founded in 2021 as a subsidiary of EST Media Holdings, OP3N imagines a world where Communities can come together to create, own, and bring their ideas to the world. OP3N’s mission is to be a Launchpad for Ideas and Communities to create meaningful experiences together. By consolidating the tools needed to mint, share and engage with NFTs and digital tokens into one vertical stack, OP3N leverages its cross-industry expertise from the entertainment, gaming and tech ecosystems, to lay the foundations for a new era of community-driven, inclusive entertainment while bringing everyone together on a journey into Web3. For more information, please visit: https://op3n.world/
About WHALE
WHALE is the omni-versal membership club for the natively digital, focused on immersing WHALE Members in the renaissance of digital art and culture. Powered by the club's native social token, $WHALE, and the club treasury, the WHALE Vault, WHALE delivers physical and metaversal content, information, and experiences for a new generation of digital enthusiasts. Established in 2020 by the pseudonymous WhaleShark, WHALE boasts over 25,000 members worldwide, all focused on the longer-term discussion and immersion of Web 3 and the revolution of true digital asset scarcity, ownership, and management.
About AMBUSH®
AMBUSH® began as an experimental jewelry line – innovative pop art-inspired designs capturing a distinct Tokyo aesthetic. With apparel created as a canvas to complete the story, AMBUSH® evolved into designing unisex collections. The brand made its Paris debut in 2015 with YOON & VERBAL being listed as two of Business of Fashion’s Top 500 people influencing the global fashion industry for 5 consecutive years from 2015, and HYPEBEAST 100 list for 8 consecutive years. In 2017 AMBUSH® was selected as one of the top 8 finalists for the LVMH PRIZE. In 2018, AMBUSH® debuted at Amazon Fashion Week Tokyo. In the same year, Kim Jones named YOON as jewelry designer for Dior Men. In 2022, AMBUSH® presented the brand’s first runway at Milan Fashion Week and launched its proprietary metaverse SILVER FCTRY. Its first POW!® NFT collection sold out in minutes, ranking it among the top 10 projects on Opensea, and the second most transacted NFT from Japan at the time of its debut.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005455/en/
Contact information
Melissa Esguerra
token2049sg@wachsman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom